Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications - Scorecard - MDSpire
Advertisement
Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications
Clinical Scorecard: Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications
At a Glance
Category
Detail
Condition
Recurrent pregnancy loss (RPL)
Key Mechanisms
Dysregulation of maternal–fetal immune tolerance, aberrant decidual immune remodeling, altered inflammasome signaling, and immune–metabolic–microbiome interactions
Target Population
Women of reproductive age experiencing recurrent pregnancy loss
Care Setting
Reproductive medicine and obstetrics clinical settings
Immune cell alterations include disrupted communication among decidual stromal cells, uterine natural killer cells, macrophages, regulatory T cells, Th17 cells, and trophoblasts.
Integration of multi-omics data with computational frameworks may improve RPL subtype classification, risk prediction, and identification of actionable pathways.
Guideline-Based Recommendations
Diagnosis
Use definitions from professional societies: ESHRE (≥2 pregnancy losses), ASRM (≥2 clinically confirmed losses), RCOG (≥3 first trimester miscarriages), Chinese consensus (≥2 consecutive losses with same spouse).
Consider comprehensive evaluation including chromosomal, immune, endocrine, and anatomical assessments.
Management
Individualized management strategies informed by immune-informed risk assessment and multi-omics biomarker discovery.
Focus on immune-centric interventions targeting dysregulated maternal–fetal immune tolerance.
Monitoring & Follow-up
Longitudinal validation of multi-omics biomarkers and immune profiles to assess risk and treatment response.
Multicenter reproducibility and standardized multi-omics pipelines recommended for consistent monitoring.
Risks
High heterogeneity and complexity in RPL etiology necessitate cautious interpretation of single-omics data.
Small cohort sizes and cross-platform heterogeneity limit current evidence robustness.
Patient & Prescribing Data
Women with recurrent pregnancy loss characterized by immune dysregulation and multi-omics heterogeneity.
Emerging evidence supports immune-informed stratification to guide individualized therapeutic approaches; however, clinical translation requires further validation.
Clinical Best Practices
Adopt multi-omics and systems biology approaches to capture complex molecular and cellular networks in RPL.
Prioritize immune-centric analytical frameworks to improve mechanistic understanding and translational relevance.
Implement standardized multi-omics pipelines and multicenter studies to enhance reproducibility and clinical applicability.
